Valneva shares hit by FDA suspension of IXCHIQ vaccine

Valneva SE

25/08/2025 08:55

** Valneva VLS.PA shares plunge 26.5% after the U.S. FDA suspended the French pharma group's chikungunya vaccine IXCHIQ

** Valneva is required to immediately halt U.S. sales and shipments of IXCHIQ after four new serious adverse events were linked to the vaccine, including cases in elderly recipients

** But Valneva maintains its 2025 product sales guidance at 170 million-180 million euros ($199 million–211 million), with IXCHIQ® contributing 7.5 million euros in H1

** Kempen sees the setback as a buying opportunity with the company's Lyme disease vaccine candidate advancing in late-stage trials

** "We view Ixchiq as a minor part of Valneva's investment thesis", the broker says

** The Lyme vaccine candidate, with phase 3 results expected by end-2025, remains the main driver for Valneva’s investment case, according to the broker

** Shares on track for their worst day since June 13, 2022

($1 = 0.8536 euros)

($1 = 0.8539 euros)

 (Reporting by Jérôme Terroy)

 ((jerome.terroy@thomsonreuters.com))